Peptilogics Makes Breakthrough in Infection Treatment with Interim Data from PLG0206 Trial at ECCMID 2023!

Peptilogics, a clinical stage biotechnology company, has successfully completed the enrollment of a Phase 1b trial of their novel therapeutic, PLG0206, to treat Periprosthetic Joint Infection (PJI) occurring after Total Knee Arthroplasty (TKA).

This open-label trial is a dose-escalating study with two cohorts of seven patients each, comparing results to historical controls. The treatment consists of a combination of Debridement, Antibiotics, and Implant Retention (DAIR) to reduce the risk of PJI and improve patient outcomes.

Peptilogics is set to present interim top-line data on their engineered peptide PLG0206 from their ongoing Phase 1b trial at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

This presentation will provide insight into the clinical safety and tolerability, as well as the reinfection rates for the low dose (3 mg/mL) cohort at the 3-month follow-up, offering a glimpse into the antimicrobial properties of PLG0206 to combat life-threatening periprosthetic joint infection (PJI). Further analysis from the high-dose cohort will be presented at a later date.

Peptilogics is working to revolutionize the current standard of care for Periprosthetic Joint Infections (PJI), which is a major clinical and economic burden on the healthcare system. By 2030, an estimated seven million total joint replacements will be performed annually in the seven major markets – requiring over 300,000 surgeries to try and resolve the infections.

Our mission is to develop a broad-spectrum curative solution that can effectively address all the challenges of bacterial biofilm in infected joints. With our innovative solution, we can bring better outcomes to patients while reducing healthcare costs.

Patients suffering from PJI have an urgent medical need that is yet to be addressed with the current standard of care. Peptilogics is proud to announce that enrollment for its Phase 1b study of PLG0206 is complete, and we are excited to develop a potentially life-changing treatment for this patient population.

About PLG0206

PLG0206 is an innovative, broad-spectrum anti-biofilm and anti-infective peptide therapy currently in clinical development for the treatment of prosthetic joint infections (PJIs). This cutting-edge therapy is designed to directly target and disrupt bacterial membranes, triggering cell death, and is capable of overcoming antibiotic resistance in a variety of bacterial pathogens, including those identified by the World Health Organization and the Centers for Disease Control and Prevention as critical, urgent, or high-priority targets.

PLG0206 has been granted FDA Orphan Drug Designation for the treatment of PJIs and has also been designated as a Qualified Infectious Disease Product (QIDP). With its powerful and effective mechanism of action, PLG0206 offers a promising solution in the fight against PJIs.

About Periprosthetic Joint Infection (PJI)

By 2030, more than seven million joint replacements will be performed each year in the major markets of the US, UK, EU, and Japan. Unfortunately, many of these surgeries will have a life-threatening consequence: a periprosthetic joint infection (PJI).

An estimated 150,000 patients will develop this condition, which often requires long-term antibiotic usage, multiple complex surgeries, and implant removal – a process that could involve over 300,000 operations. With a current standard of care that has a four-year failure rate of up to 60%, PJI can be an incredibly dangerous condition, with a five-year mortality rate of 25%.

About Peptilogics

Peptilogics is revolutionizing the treatment of life-threatening diseases with its cutting-edge peptide therapeutic candidates. By leveraging their expertise in both biology and pharmaceuticals, as well as utilizing artificial intelligence algorithms and purpose-built supercomputers, Peptilogics is rapidly advancing its therapeutic pipeline and propelling the discovery of new treatments to unprecedented levels.

With the backing of some of the world’s top visionary investors, including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and the Cystic Fibrosis Foundation, Peptilogics is striving to make a lasting impact on the lives of patients everywhere.

Leave a Comment